Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE BTX opened at $0.21 on Friday. The firm has a fifty day moving average of $0.94 and a 200 day moving average of $1.50. The firm has a market cap of $12.07 million, a PE ratio of -0.19 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.